Coherus Oncology (CHRS) Jefferies 2024 Global Healthcare Conference summary

Corporate strategy and business model

• Focused exclusively on innovative oncology, divesting non-core assets like ophthalmology to sharpen portfolio focus.

• Fully integrated commercial-stage company with accelerating sales from LOQTORZI and UDENYCA.

• Robust pipeline includes LOQTORZI, Casdozokitug, CHS-114 (CCR8), and ILT4, targeting solid tumors.

• Strategic collaborations with partners like Junshi, Inovio, and Cancer Research Institute to expand indications and share development costs.

• Capital allocation prioritized for clinical proof of concept and debt reduction, with debt lowered from $250M to $37.5M in three months.

Pipeline and clinical development

• CCR8 antibody targets tumor-infiltrating Tregs, showing safety and proof of mechanism in Phase I; dose expansion ongoing in head and neck cancer.

• Casdozokitug (IL-27 antagonist) demonstrated safety, immune activation, and monotherapy responses in lung, liver, and renal cancers; combination studies with toripalimab underway.

• ILT4 program targets myeloid checkpoint, aiming to remove tumor immune suppression; clinical entry planned in coming months.

• Multiple registrational studies for LOQTORZI are partner-funded, reducing internal development costs.

• Upcoming catalysts include data from combination studies and new trial initiations in 2024.

Commercial performance and product launches

• LOQTORZI is the only FDA-approved treatment for nasopharyngeal carcinoma, now standard of care with Category 1 NCCN designation.

• Market penetration for LOQTORZI expected to ramp over 2.5–3 years, targeting $150–200M annual peak sales.

• UDENYCA franchise expanded with prefilled syringe, auto-injector, and on-body injector, driving 64% revenue growth from Q1 2023 to Q1 2024.

• Market share for UDENYCA increased from 10.5% to over 25% in one year, with further growth projected.

• Enhanced payer coverage and differentiated product presentations support continued commercial momentum.